Merck Insomnia Treatment Shows Positive Phase III Results

In the study, investigative insomnia medicine Suvorexant improved patients' ability to fall and stay asleep.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from two pivotal Phase III efficacy trials for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. In the studies, suvorexant significantly reduced the time it took patients to fall asleep and increased the time that patients stayed asleep as early as the first night and at the three-month time point compared to placebo.

No votes yet
Syndicate content